Innovative clinical trial designs to rationalize TB vaccine development

Tuberculosis

Volumn 95, Issue 3, 2015, Pages 352-357

  Ellis, R D ^a   Hatherill, M ^b   Tait, D ^c   Snowden, M ^a   Churchyard, G ^d,e   Hanekom, W ^f   Evans, T ^a   Ginsberg, A M ^a  

^a AERAS   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Aeras   (South Africa)

^d AURUM INSTITUTE   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Clinical development; Prevention of infection; Prevention of recurrence; Proof of concept; Trial design; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE;

ARTICLE; BCG VACCINATION; CLINICAL TRIAL (TOPIC); HUMAN; INFECTION PREVENTION; INFECTION RISK; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; DRUG DEVELOPMENT; IMMUNOLOGY; MASS COMMUNICATION; METHODOLOGY; MICROBIOLOGY; PATIENT SELECTION; RECURRENT DISEASE; RISK FACTOR; SAMPLE SIZE; TRANSMISSION; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIFFUSION OF INNOVATION; DRUG DISCOVERY; HUMANS; PATIENT SELECTION; RECURRENCE; RESEARCH DESIGN; RISK FACTORS; SAMPLE SIZE; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84929292991     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2015.02.036     Document Type: Note

References (44)

1. WHO Global tuberculosis report 2014 http://www.who.int/tb/publications/global-report/en/
2. A. Zumla, M. Raviglione, R. Hafner, and C.F. von Reyn Tuberculosis N Engl J Med 368 8 2013 Feb 21 745 755
3. G. Hussey, T. Hawkridge, and W. Hanekom Childhood tuberculosis: old and new vaccines Paediatr Respir Rev 8 2007 148 154
4. R. Rustomjee, R. McLeod, and W. Hanekom Key issues in the clinical development and implementation of TB vaccines in South Africa Tuberculosis (Edinb) 92 5 2012 359 364
5. M.D. Tameris, M. Hatherill, B.S. Landry, T.J. Scriba, M.A. Snowden, S. Lockhart, J.E. Shea, J.B. McClain, G.D. Hussey, W.A. Hanekom, H. Mahomed, H. McShane MVA85A 020 Trial Study Team Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial Lancet 6 13 2013 60177 60184
6. L. Barker, L. Hessel, and B. Walker Rational approach to selection and clinical development of TB vaccine candidates Tuberculosis 92 Suppl. 1 March 2012 S25 S29
7. H. McShane, and A. Williams A review of preclinical animal models utilized for TB vaccine evaluation in the context of recent human efficacy data Tuberculosis 94 2 2014 105 110 10.1016/j.tube.2013.11.003
8. A.S. Dharmadhikari, R.J. Basaraba, M.L. Van Der Walt, K. Weyer, M. Mphahlele, K. Venter, P.A. Jensen, M.W. First, S. Parsons, D.N. McMurray, I.M. Orme, and E.A. Nardell Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis Tuberculosis (Edinb) 91 4 2011 329 338 10.1016/j.tube.2011.03.002
9. S.A. Harris, J. Meyer, I. Satti, L. Marsay, I.D. Poulton, R. Tanner, A.M. Minassian, H.A. Fletcher, and H. McShane Evaluation of a human BCG Challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination J Infect Dis 209 8 2014 1259 1268
10. R. McNerney, M. Maeurer, I. Abubakar, B. Marais, T.D. McHugh, N. Ford, K. Weyer, S. Lawn, M.P. Grobusch, Z. Memish, S.B. Squire, G. Pantaleo, J. Chakaya, M. Casenghi, G.B. Migliori, P. Mwaba, L. Zijenah, M. Hoelscher, H. Cox, S. Swaminathan, P.S. Kim, M. Schito, A. Harari, M. Bates, S. Schwank, J. O'Grady, M. Pletschette, L. Ditui, R. Atun, and A. Zumla Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities J Infect Dis 205 Suppl. 2 2012 S147 S158
11. K. Ewer, K.A. Millington, J.J. Deeks, L. Alvarez, G. Bryant, and A. Lalvani Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis Am J Respir Crit Care Med 174 2006 831 839
12. H. Mahomed, R. Ehrlich, T. Hawkridge, M. Hatherill, L. Geiter, F. Kafaar, D.A. Abrahams, H. Mulenga, M. Tameris, H. Geldenhuys, W.A. Hanekom, S. Verver, and G.D. Hussey TB incidence in an adolescent cohort in South Africa PLoS One 8 2013 e59652
13. H. Mahomed, T. Hawkridge, S. Verver, L. Geiter, M. Hatherill, D.A. Abrahams, R. Ehrlich, W.A. Hanekom, G.D. Hussey SATVI Adolescent Study Team Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa Int J Tuberc Lung Dis 15 2011 331 336
14. ®-TB gold in-tube conversion and reversion in a cohort of south african adolescents Am J Respir Crit Care Med 191 5 2015 Mar 1 584 591
15. R.I. Menzies, K. Schwartzman, and M. Pai Immune-based tests for tuberculosis S. Schaaf, A.I. Zumla, Tuberculosis: a comprehensive clinical reference 2009 Elsevier 179 185
16. M. Pai Serial testing with TB interferon-gamma release assays: toward a nuanced understanding Chest 142 2012 1366 1367
17. G.H. Mazurek, J. Jereb, A. Vernon, P. LoBue, and S. Goldberg Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States MMWR Recomm Rep 2010 59 2010 1 25
18. M. Pai, C.M. Denkinger, S.V. Kik, M.X. Rangaka, A. Zwerling, O. Oxlade, J.Z. Metcalfe, A. Cattamanchi, D.W. Dowdy, K. Dheda, and N. Banaei Gamma interferon release assays for detection of Mycobacterium tuberculosis infection Clin Microbiol Rev 27 1 2014 3 20
19. J.Z. Metcalfe, A. Cattamanchi, C.E. McCulloch, J.D. Lew, N.P. Ha, and E.A. Graviss Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice Am J Respir Crit Care Med 187 2013 206 211
20. A. Zwerling, A. Benedetti, M. Cojocariu, F. McIntosh, F. Pietrangelo, M.A. Behr, K. Schwartzman, D. Menzies, and M. Pai Repeat IGRA testing in Canadian health workers: conversions or unexplained variability? PLoS One 8 2013 e54748
21. H. Mahomed, T. Hawkridge, S. Verver, D. Abrahams, L. Geiter, M. Hatherill, R. Ehrlich, W.A. Hanekom, and G.D. Hussey The tuberculin skin test versus QuantiFERON TB Gold(R) in predicting tuberculosis disease in an adolescent cohort study in South Africa PLoS One 6 2011 e17984
22. S. Machingaidze, S. Verver, H. Mulenga, D.A. Abrahams, M. Hatherill, W. Hanekom, G.D. Hussey, and H. Mahomed Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents Am J Respir Crit Care Med 186 2012 1051 1056
23. P.E.M. Fine Variation in protection by BCG: implications of and for heterologous immunity Lancet 346 1995 1339 1345
24. P. Mangtani, I. Abubakar, C. Ariti, R. Beynon, L. Pimpin, P.E. Fine, L.C. Rodrigues, P.G. Smith, M. Lipman, P.F. Whiting, and J.A. Sterne Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials CID 58 4 2014 470 480
25. A. Soysal, K.A. Millington, M. Bakir, D. Dosanjh, Y. Aslan, J.J. Deeks, S. Efe, I. Staveley, K. Ewer, and A. Lalvani Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study Lancet 366 2005 1443 1451
26. M. Eisenhut, S. Paranjothy, I. Abubakar, S. Bracebridge, M. Lilley, R. Mulla, K. Lack, D. Chalkley, and M. McEvoy BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay Vaccine 27 2009 6116 6120
27. R. Basu Roy, G. Sotgiu, N. Altet-Gómez, M. Tsolia, E. Ruga, S. Velizarova, and B. Kampmann Identifying predictors of interferon-gamma release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette-Guerin?: a pTB-NET collaborative study Am J Respir Crit Care Med 186 2012 378 384
28. M.L. Barreto, S.M. Pereira, D. Pilger, A.A. Cruz, S.S. Cunha, C. Sant'Anna, M.Y. Ichihara, B. Genser, and L.C. Rodrigues Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial Vaccine 29 2011 4875 4877
29. S.M. Pereira, M.L. Barreto, D. Pilger, A.A. Cruz, C. Sant'Anna, M.A. Hijjar, M.Y. Ichihara, A.C. Santos, B. Genser, and L.C. Rodrigues Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial Lancet Infect Dis 12 2012 300 306
30. L.C. Rodrigues, S.M. Pereira, S.S. Cunha, B. Genser, M.Y. Ichihara, S.C. de Brito, M.A. Hijjar, I. Dourado, A.A. Cruz, C. Sant'Anna, A.L. Bierrenbach, and M.L. Barreto Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial Lancet 366 2005 1290 1295
31. S. Verver, R.M. Warren, N. Beyers, M. Richardson, G.D. van der Spuy, M.W. Borgdorff, D.A. Enarson, M.A. Behr, and P.D. van Helden Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis Am J Respir Crit Care Med 171 2005 1430 1435
32. S. Charalambous, A.D. Grant, V. Moloi, R. Warren, J.H. Day, P. van Helden, R.J. Hayes, K.L. Fielding, K.M. De Cock, R.E. Chaisson, and G.J. Churchyard Contribution of reinfection to recurrent tuberculosis in South African gold miners Int J Tuberc Lung Dis 12 8 2008 942 948
33. A.J. Nunn, P.P.J. Phillips, and D.A. Mitchison Timing of relapse in short-course chemotherapy trials for tuberculosis Int J Tuberc Lung Dis 14 2 2010 241 242
34. R. Panjabi, G.W. Comstock, and J.E. Golub Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk Int J Tuberc Lung Dis 11 8 2007 828 837
35. M.L. Lambert, E. Hasker, A. Van Deun, D. Roberfroid, M. Boelaert, and P. Van der Stuyft Recurrence in tuberculosis: relapse or reinfection? Lancet Inf Dis 3 2003 282 287
36. R.A. Breen, C.J. Smith, H. Bettinson, S. Dart, B. Bannister, M.A. Johnson, and M.C. Lipman Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection Thorax 59 2004 704 707
37. R. Wood, S.D. Lawn, J. Caldwell, R. Kaplan, K. Middelkoop, and L.G. Bekker Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status PLoS One 6 10 2011 e25098
38. M.X. Rangaka, K.A. Wilkinson, J.R. Glynn, D. Ling, D. Menzies, J. Mwansa-Kambafwile, K. Fielding, R.J. Wilkinson, and M. Pai Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis Lancet Infect Dis 12 2012 45 55
39. P.L. Lin, J. Dietrich, E. Tan, R.M. Abalos, J. Burgos, C. Bigbee, M. Bigbee, L. Milk, H.P. Gideon, M. Rodgers, C. Cochran, K.M. Guinn, D.R. Sherman, E. Klein, C. Janssen, J.L. Flynn, and P. Andersen The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection J Clin Invest 122 1 2012 303 314 10.1172/JCI46252
40. R.N. Coler, S. Bertholet, S.O. Pine, M.T. Orr, V. Reese, H.P. Windish, C. Davis, M. Kahn, S.L. Baldwin, and S.G. Reed Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment J Infect Dis 207 8 2012 Apr 15 1242 1252 10.1093/infdis/jis425
41. J.A. Langermans, T.M. Doherty, R.A. Vervenne, T. van der Laan, K. Lyashchenko, R. Greenwald, E.M. Agger, C. Aagaard, H. Weiler, D. van Soolingen, W. Dalemans, A.W. Thomas, and P. Andersen Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6 Vaccine 23 21 2005 2740 2750
42. T. Hoang, C. Aagaard, J. Dietrich, J.P. Cassidy, G. Dolganov, G.K. Schoolnik, C.V. Lundberg, E.M. Agger, and P. Andersen ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and Post-Exposure tuberculosis vaccination PLoS One 8 12 2013 e80579
43. R. Rustomjee, B. McClain, M.J. Brennan, R. McLeod, C.M. Chetty-Makkan, H. McShane, W. Hanekom, G. Steel, H. Mahomed, A.M. Ginsberg, J. Shea, S. Lockhart, S. Self, and G.J. Churchyard Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents Tuberc (Edinb) 93 2 2013 136 142
44. P.B. Gilbert, D. Grove, E. Gabriel, Y. Huang, G. Gray, S.M. Hammer, S.P. Buchbinder, J. Kublin, L. Corey, and S.G. Self A sequential phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine Regimens Stat Commun Infect Dis 3 1 2011 1037